VIBRANTNCT07920367
Non-Invasive Biomarker Monitoring in UC on Biologics
StatusNot Yet Recruiting
PhaseNot specified
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Faecal VOC discrimination of therapeutic versus sub-therapeutic biologic trough concentration
Timeframe: From enrollment to the end of treatment at 8 weeks
Secondary (6)
Urinary VOC discrimination of therapeutic versus sub-therapeutic trough concentration (cross-validated AUROC, 95% CI)
Change in cross-validated AUROC when VOC features are added to models containing FCP, CRP and cytokines
Association between faecal VOC features and microbiota composition and diversity (FDR-adjusted)
Association between faecal VOC features and blood DNA methylation, including interaction with remission/relapse status (FDR-adjusted
Faecal VOC discrimination of remission versus relapse (cross-validated AUROC, 95% CI)
Show 1 moreShow less
Difference in cross-validated AUROC between faecal and urinary VOC models (paired DeLong test)
Arms and interventions
Infliximab
Adults with UC on maintenance IV infliximab. Standard-care maintenance intravenous therapy; not assigned or altered by the study.
Vedolizumab
Adults with UC on maintenance IV vedolizumab. Standard-care maintenance intravenous therapy; not assigned or altered by the study.
Sites
1 site in 1 country
- University Hospitals Coventry and Warwickshire NHS TrustCoventry, United Kingdom